Akero Therapeutics Inc (NASDAQ: AKRO) kicked off on Friday, down -8.15% from the previous trading day, before settling in for the closing price of $39.99. Over the past 52 weeks, AKRO has traded in a range of $17.86-$58.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -14.49%. With a float of $70.68 million, this company’s outstanding shares have now reached $72.38 million.
In an organization with 63 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Akero Therapeutics Inc (AKRO) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Akero Therapeutics Inc is 11.23%, while institutional ownership is 86.61%. The most recent insider transaction that took place on Mar 25 ’25, was worth 4,085,804. In this transaction Director of this company bought 91,309 shares at a rate of $44.75, taking the stock ownership to the 1,091,309 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Director bought 58,691 for $43.01, making the entire transaction worth $2,524,417. This insider now owns 1,150,000 shares in total.
Akero Therapeutics Inc (AKRO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -14.49% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -8.19% during the next five years compared to -5.28% drop over the previous five years of trading.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Take a look at Akero Therapeutics Inc’s (AKRO) current performance indicators. Last quarter, stock had a quick ratio of 19.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -0.97 in the next quarter and is forecasted to reach -4.63 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Let’s dig in a bit further. During the last 5-days, its volume was 1.48 million. That was better than the volume of 1.37 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.11%. Additionally, its Average True Range was 2.55.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 41.53%, which indicates a significant increase from 0.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.33% in the past 14 days, which was lower than the 121.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $46.92, while its 200-day Moving Average is $32.46. However, in the short run, Akero Therapeutics Inc’s stock first resistance to watch stands at $38.92. Second resistance stands at $41.10. The third major resistance level sits at $42.22. If the price goes on to break the first support level at $35.62, it is likely to go to the next support level at $34.50. Assuming the price breaks the second support level, the third support level stands at $32.32.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
The company with the Market Capitalisation of 2.92 billion has total of 79,620K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -252,060 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -70,020 K.
